Impact of human serum albumin on oritavancin in vitro activity against enterococci.

Article Details

Citation

Copy to clipboard

McKay GA, Beaulieu S, Sarmiento I, Arhin FF, Parr TR Jr, Moeck G

Impact of human serum albumin on oritavancin in vitro activity against enterococci.

Antimicrob Agents Chemother. 2009 Jun;53(6):2687-9. doi: 10.1128/AAC.00197-09. Epub 2009 Apr 6.

PubMed ID

19349514 [ View in PubMed

]

Abstract

Oritavancin is a lipoglycopeptide with activity against gram-positive pathogens including vancomycin-resistant enterococci. The impact of human serum albumin (HSA) on oritavancin activity against enterococci was compared to those of vancomycin, daptomycin, teicoplanin, and linezolid in vitro using MIC and time-kill methods. Oritavancin MICs increased between 0- and 8-fold in the presence of HSA. In time-kill assays with HSA, oritavancin retained activity, killing or inhibiting enterococci more rapidly than did comparators when peak concentrations were simulated.

DrugBank Data that Cites this Article

Drug Carriers

Drug	Carrier	Kind	Organism	Pharmacological Action	Actions
Oritavancin	Serum albumin	Protein	Humans	Unknown	Binder	Details